丁桂凝胶膏剂与丁桂活络膏体外释放及透皮特性比较研究

目的比较丁桂活络膏与其改良剂型丁桂凝胶膏剂的体外释放及透皮特性。方法分别采用微孔滤膜或Strat-M膜及改进的Franz扩散池进行体外释放及透皮试验,用HPLC法定量分析制剂中君药羌活的有效成分羌活醇的量,测定2种剂型的体外释放度、透皮量及透皮率。结果丁桂凝胶膏剂的透皮方程为=9.208-18.50,=0.948,体外累积释放度、透皮量、透皮率分别为85.34%、0.661 8 mg/g、65.67%;丁桂活络膏的透皮方程为=4.285-6.704,=0.977,体外累积释放度、透皮量、透皮率分别为67.87%、0.181 6 mg/g、31.35%。结论丁桂凝胶膏剂的体外释放度、透皮量及透皮率均优于丁桂活络膏,透皮特性明显优于原剂型,且凝胶膏剂不易过敏,贴敷方便。     

运用朱良春“丁桂硝黄散”外敷治疗肠梗阻体会

<正>肠梗阻为临床常见急腹症,主要因肠内容物在肠道中通过受阻而发病,常表现为腹痛、腹胀、恶心、呕吐、排气排便减少或停止等,可引起梗阻肠段解剖和功能性改变,进而出现体液和电解质丢失、肠壁坏死和继发感染,甚或致毒血症、休克、死亡。肠梗阻属于中医学"肠痹""关格""肠结""腹胀"等范畴,其发生机制为湿热蕴结或正气亏虚,导致胃通降失常、腑气不通。肠梗阻治疗以"通"为要,但又不限于"通",需处理好扶正与通便的关系。扶正要辨证,通便要掌握好     

无铅丁桂膏的工艺研究

目的氧化锌代替铅丹制备无铅膏药基质,分步提取丁桂膏处方中的有效成分,最后混合滩涂制成无铅丁桂膏。方法按L9(34)正交试验表优选膏药基质的无铅化工艺,以水蒸气蒸馏法提取丁香、肉桂、白芷中的挥发油,以60⁸0%的乙醇提取川乌、草乌药材及丁香、肉桂、白芷药渣中的醇溶性成分并浓缩成稠膏,乳香、没药、樟脑、冰片直接粉碎成细粉最后加入。结果正交试验显示无铅膏药基质最佳工艺条件为麻油于330℃下熬炼3h,氧化锌与麻油高温聚混物配比(g/mL)为1∶5,反应时间为20min。挥发油的最佳提取工艺为加10倍量水提取4.5h。醇溶性成分的最佳提取工艺为加入10倍量的70%的乙醇回流提取60min。结论药物有效成分与基质混合后制成的无铅丁桂膏,软化点和持黏力适宜,能代替黑膏药发挥治疗作用。     

单氏丁桂散促进疮疡愈合的实验研究

目的：观察单氏丁桂散对实验动物的消炎，促进伤口愈合的作用。方法：方法：根据《药理实验方法学》进行抗炎，促进伤口愈合实验和急性毒性实验。病理学检查，抗菌MIC测定。结果：单氏丁桂散对多种致炎剂引起的炎性水肿有明显的抑制作用；明显缩短豚鼠伤口愈合时间；明显提高溶菌酶的活性；促进动物创面的白细胞，浆细胞浸泡，毛细血管，胶原纤维增生。结论：单氏丁桂散是一种抗炎，促进伤口愈合，低毒的外用制剂。     

丁桂活络凝胶膏的质量标准研究

目的:建立丁桂活络凝胶膏的质量标准。方法:采用薄层色谱(TLC)法鉴别制剂中的木香、羌活、独活;采用高效液相色谱法测定制剂中延胡索乙素的含量:色谱柱为Waters Symmetry Shield C18(250 mm×4.6 mm,5μm),流动相为甲醇-0.1%磷酸溶液(p H6.0,50∶50,V/V),流速为1.0 ml/min,检测波长为280 nm,柱温为25℃,进样量为10μl。结果:木香、羌活、独活的TLC图斑点清晰、分离度好。延胡索乙素的质量浓度在10.58⁵2.90μg/ml范围内与峰面积积分值呈良好线性关系(r=0.999 9);精密度、稳定性、重复性试验的RSD均≤0.72%,平均加样回收率为100.07%,RSD=0.65%(n=9)。结论:所建质量标准可用于丁桂活络凝胶膏的质量控制。     

Effectiveness and Safety of Umbilicus Treatment with Modified Dinggui Powder(加味丁桂散)in Patients with Chronic Nonbacterial Prostatitis:A Randomized,Double-Blind,Placebo-Controlled Clinical Trial

Objective:To evaluate the effectiveness and safety of Chinese herbal external umbilicus treatment with Modified Dinggui Powder(加味丁桂散,MDGP)in patients with chronic nonbacterial prostatitis(CNP).Methods:A randomized,double-blind,placebo-controlled clinical trial was conducted among 72 patients with CNP.Participants were randomly allocated to a treatment group and a placebo group using computer software in a 1:1 ratio,and received either MDGP external umbilicus treatment(MDGP group,36 cases)or placebo(control group,36 cases)at acupoints Shenque(CV 8),twice a week for 4 weeks.In addtion,patients all received herbal medicine treatment twice a day for 4 weeks.The primary outcome was the US National Institutes of Health Chronic Prostatitis Symptom Scores Index(NIH-CPSI)with a questionnaire at weeks 2 and 4.The secondary outcomes including prostatic fluid examination(white blood cells and lecithin bodies),the clinical efficacy evaluation,and the adverse events were also assessed during the entire trial.Results:The NIH-CPSI scores regarding pain or discomfort scores showed greater improvement in the MDGP group than placebo control group at weeks 2(P=0.001)and week 4(P=0.004),respectively.NIH-CPSI scores of symptom severity,total scores and leukocytes number in the prostatic fluid in the MDGP group were significantly improved(P<0.05).There was no statistical difference in the urinary symptoms,quality of life,lecithin and other scores between two groups(P>0.05).The clinical effective rate was 73.53%(25/34)in the MDGP group,which was significally higher than the placebo control group with 48.39%(25/31,P<0.05).Patients were blinded successfully,and no serious adverse effects were found during the trial.Conclusion:A 4-week course of umbilicus treatment with modified Dinggui Powder seems to relieve pain and symptom severity effectively and increase the amount of leukocytes number in patients with CNP(Trial registration No.ChiCTRI 800014687).